Dr. Ferrarotto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Fc9.2063 (Faculty Center Building)
Houston, TX 77030Phone+1 713-745-6774Fax+1 713-792-1220- Is this information wrong?
Education & Training
- University of Campinas Faculty of MedicineClass of 2006
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2016 - 2024
- OK State Medical License 2020 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) Start of enrollment: 2015 Dec 29
- Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer Start of enrollment: 2017 Jul 12
- Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2019 Jul 22
- Join now to see all
Publications & Presentations
PubMed
- Complete Response to Immunotherapy Using Pembrolizumab in a Patient With Conjunctival Squamous Cell Carcinoma With Nodal Metastasis.Janet Fan, Hila Goldberg, Carlos A Torres-Cabala, John Stewart, Matthew Debnam, Tracy Lu, Priyadharsini Nagarajan, Eloisa Catherine Crouse, Renata Ferrarotto, Bita Esm...> ;Ophthalmic Plastic and Reconstructive Surgery. 2024 Apr 29
- First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report.Camilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Jordi Rodon Ahnert, Luana G de Sousa, Adel K El-Naggar, Renata Ferrarotto> ;JCO Precision Oncology. 2024 Apr 1
- Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma.Eduardo A Dal Lago, Zixi Yang, Camilla O Hoff, Flavia Bonini, Matthew Sawyer, Kaiwen Wang, Whitney Lewis, Kareem A Wahid, Ehab Y Hanna, Suprateek Kundu, Luana G Sousa,...> ;Oral Oncology. 2024 Apr 1
- Join now to see all
Journal Articles
- Risk and Clinical Risk Factors Associated with Late Lower Cranial Neuropathy in Long-Term Oropharyngeal Squamous Cell Carcinoma SurvivorsRyan P Goepfert, Stephen Y Lai, Renata Ferrarotto, Erich M Sturgis, JAMA Otolaryngology–Head & Neck Surgery
- Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019Renata Ferrarotto, MD, JAMA Oncology
- PI3‐Kinase Pathway Biomarkers in Oral Cancer and Tumor Immune CellsBonnie S Glisson, Jeffrey Myers, N Jr William, Renata Ferrarotto, Head & Neck
- Join now to see all
Lectures
- Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.2019 ASCO Annual Meeting - 6/1/2019
- Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).2019 ASCO Annual Meeting - 6/1/2019
- ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mut...2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Authored Content
- Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019August 2020
- Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019August 2020
Press Mentions
- MD Anderson Research Highlights: ASCO 2023 Special EditionMay 25th, 2023
- Scientists Share ‘Comprehensive’ Map of Volcanoes on Venus — All 85,000 of ThemMarch 28th, 2023
- Mount Sinai Health System Recognized by Fortune as One of “America’s Most Innovative Companies 2023”March 28th, 2023
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: